文献速递胸部肿瘤泌尿男性生殖肿瘤骨软组织肉瘤与黑色素瘤

PD-1/PD-L1阻断应答者的进展风险主要由应答深度分层:2127例黑色素瘤、肾细胞癌和NSCLC全国队列研究

Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.
PubMed 文献 · Eur J Cancer · 2026-06-05

这项全国性人群队列研究纳入2127例对PD-1/PD-L1阻断治疗达到客观应答的转移性黑色素瘤、肾细胞癌或非小细胞肺癌患者,评估应答深度以外的肿瘤类型和传统基线特征是否提供额外进展预后信息。结果显示,完全缓解与部分缓解类别内的无进展生存轨迹在三种肿瘤类型间高度相似,应答深度是各肿瘤队列中与进展风险相关的最强独立因素,肿瘤类型和传统基线预后因素在已知应答深度后提供的额外分层信息有限。

要点

  • 在三种肿瘤应答者中,完全缓解与部分缓解的无进展生存轨迹高度相似。
  • 应答深度是各肿瘤队列中与进展风险相关的最强独立因素。
  • 已知应答深度后,肿瘤类型和传统基线因素额外预后信息有限。

核心结论

  • 在转移性黑色素瘤、肾细胞癌和非小细胞肺癌的PD-1/PD-L1阻断应答者中,已知应答深度后,肿瘤类型和传统基线预后因素对进展风险的额外分层有限。
  • 在所研究的肿瘤类型中,应答持久性主要与应答深度相关,而非其他已知临床特征。

研究设计与样本

  • 全国性、基于人群的队列研究,纳入接受PD-1/PD-L1单药或双免疫检查点阻断治疗的转移性黑色素瘤、肾细胞癌或非小细胞肺癌成人患者。
  • 分析限于研究者评估的RECIST完全缓解或部分缓解的应答者,结局在5年时进行行政删失。
  • 使用Kaplan-Meier和Cox模型评估预设基线和治疗中变量与无进展生存和总生存的关联,并评估跨肿瘤类型的一致性。

主要发现

  • 在2127例应答者中,完全缓解和部分缓解类别内的无进展生存轨迹在黑色素瘤、肾细胞癌和非小细胞肺癌间高度相似。
  • 在总体人群中具有预后价值的预设变量(包括体能状态和治疗线数)在已知应答深度后提供的额外预后信息有限。
  • 应答深度(完全缓解 vs 部分缓解)是每个肿瘤队列中与进展风险相关的最强独立因素。

临床怎么用

  • 对于达到客观应答的患者,临床随访和干预策略可优先基于应答深度进行风险分层。
  • 研究结果支持前瞻性评估应答指导的随访策略和旨在加深应答的干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Among responders to PD-1/PD-L1 blockade, it remains unclear whether tumour type and traditional baseline patient and tumour characteristics provide additional prognostic information for progression risk beyond response depth. METHODS: In this nationwide, population-based cohort study, we identified adults with metastatic melanoma (MM), renal cell carcinoma (RCC), or non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 monotherapy or dual checkpoint blockade. Analyses were restricted to responders by investigator-assessed RECIST (complete or partial response) with outcomes administratively censored at 5 years. Prespecified baseline and on-treatment variables were evaluated for associations with progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier and Cox models and assessed for consistency across tumour types. RESULTS: Among 2127 responders, PFS trajectories within response depth categories (complete response and partial response) were highly similar across MM, RCC, and NSCLC. Prespecified variables with prognostic value in the overall population, including performance status and treatment line, provided limited additional prognostic information once response depth was known. Depth of response (complete vs partial) was the strongest independent factor associated with progression risk within each tumour cohort. CONCLUSIONS: Among patients with MM, RCC, or NSCLC who achieved an objective response to PD-1/PD-L1 blockade, tumour type and traditional baseline prognostic factors provided limited additional stratification of progression risk once response depth was known. These findings suggest that, within the tumour types studied, response durability is primarily associated with response depth rather than other known clinical features, supporting prospective evaluation of response-guided follow-up strategies and interventions designed to deepen responses.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Andersen R, Jespersen MS, Presti M, et al. Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC. Eur J Cancer. 2026. PMID: 42284973. doi:10.1016/j.ejca.2026.116872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。